Herceptin Injection 440 mg (Trastuzumab)

Adult administration

Breast Cancer Metastatic Breast Cancer 1-Week Schedule: Initial loading dose: 4 mg/kg. Maintenance dose: 2 mg/kg weekly (to be started one week after the initial loading dose). Breast Cancer Metastatic Breast Cancer 3-Week Schedule: Initial loading dose: 8 mg/kg. Maintenance dose: 6 mg/kg every three weeks (to be started three weeks after the initial loading dose). Early Breast Cancer 3-Week Schedule: Initial loading dose: 8 mg/kg. Then, maintain with doses every three weeks.

This drug may affect cardiac function, so caution is especially required for patients with heart failure or cardiac dysfunction. Patients at high risk of cardiac disease should undergo cardiac function tests before treatment and also have their heart condition monitored regularly during treatment. If cardiac function continues to decline during the administration of this drug, consideration should be given to discontinuing it. Allergic reactions or infusion-related side effects may occur during administration, so the patient's condition should be closely monitored during infusion. If serious reactions such as difficulty breathing or hypotension occur, administration should be stopped immediately and appropriate treatment should be provided. Pulmonary-related side effects may also occur rarely, so patients with respiratory symptoms should be particularly cautious. This drug should not be administered to patients with hypersensitivity to certain components, severe difficulty in breathing, neonates, or premature infants. The risk of cardiac toxicity increases when used in combination with anthracycline-based drugs, so cardiac function should be closely monitored during combination therapy. This drug may pose risks to the fetus in pregnant or potentially pregnant women, so effective contraception is necessary during and for a period after treatment. Use in breastfeeding is not recommended, and special care is required when administering to children or the elderly. Dizziness or drowsiness can occur during driving or operating machinery, so caution should be exercised when symptoms are present. This drug should be prepared in a sterile state, and during reconstitution and dilution, the specified solution and method must be strictly adhered to. No drug interactions have been reported between this drug and others, but consulting with a specialist is recommended for concurrent use. Adverse reactions reported after administration include infections, blood abnormalities, gastrointestinal symptoms, skin reactions, and neurological symptoms; if symptoms are severe or persistent, consult medical personnel.

Serious side effects

• Hives
• angioedema
• difficulty breathing
• severe swelling (edema)
• hypertension
• hypotension
• wheezing
• bronchospasm
• ventricular tachycardia
• decreased oxygen saturation

Mild side effects

• Nausea
• muscle pain
• anemia
• neutropenia
• leukopenia
• thrombocytopenia
• insomnia
• anxiety
• depression
• dizziness

This drug should be stored in a sealed container to avoid contact with air. Additionally, it is important to store it at a refrigerator temperature between 2°C to 8°C to maintain the drug's effectiveness.

Appearance

A colorless injectable solution with a white to light yellow freeze-dried substance filled in a vial, which, when reconstituted with the solvent, appears as a colorless to pale yellow clear or slightly cloudy liquid.

Package unit

1 vial/box